Peter J.P. Croucher

2.4k citations

9 papers · 1.5k indexed · 2 hit papers · h-index 6

Co-authors: Stefan Schreiber Jochen Hampe Andrew Cuthbert Christopher G. Mathew Silvia Mascheretti Muddassar M. Mirza Kathy King Alastair Forbes
Topics: Acute Myeloid Leukemia Research (4 papers)Inflammatory Bowel Disease (4 papers)Cancer Genomics and Diagnostics (3 papers)
Cited by: Genetics Immunology Epidemiology
Journals: Proceedings of the National Academy of Sciences The Lancet Blood
Partner nations: Germany United States United Kingdom

In The Last Decade

Peter J.P. Croucher

9 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations

2001 837 citations Jochen Hampe, Andrew Cuthbert et al. The Lancet profile →
The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease

2002 523 citations Andrew Cuthbert, Sheila Fisher et al. Gastroenterology profile →

Peers

Countries citing papers authored by Peter J.P. Croucher

Since Specialization

Citations

This map shows the geographic impact of Peter J.P. Croucher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J.P. Croucher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J.P. Croucher more than expected).

Fields of papers citing papers by Peter J.P. Croucher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J.P. Croucher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J.P. Croucher. The network helps show where Peter J.P. Croucher may publish in the future.

Co-authorship network of co-authors of Peter J.P. Croucher

This figure shows the co-authorship network connecting the top 25 collaborators of Peter J.P. Croucher. A scholar is included among the top collaborators of Peter J.P. Croucher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J.P. Croucher. Peter J.P. Croucher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia 2023 ·Annals of Hematology ·Peter J.P. Croucher,Maya Ridinger,Pamela S. Becker,Tara L. Lin,Sandra Silberman,Eunice S. Wang,Amer M. Zeidan	6
2	Predictive Biomarkers of Response to the Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Decitabine in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) 2021 ·Blood ·Amer M. Zeidan,Maya Ridinger,Peter J.P. Croucher,Errin Samuëlsz,Mark G. Erlander,Katherine Ruffner,Eunice S. Wang	1
3	Abstract 2019: Oxidative phosphorylation (OXPHOS) dependency predicts response to the Polo-like kinase 1 (PLK1) inhibitor onvansertib in a phase 1b/2 of relapsed/refractory acute myeloid leukemia (R/R AML) 2020 ·Cancer Research ·Peter J.P. Croucher,Errin Samuëlsz,(unknown),(unknown),(unknown),Maya Ridinger,Mark G. Erlander	2
4	Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) 2019 ·Blood ·Amer M. Zeidan,Gary J. Schiller,Tara L. Lin,Pamela S. Becker,Prapti A. Patel,Eunice S. Wang,Alexander I. Spira,Michaela L. Tsai,Maya Ridinger,Peter J.P. Croucher,Mark G. Erlander,Sandra Silberman	2
5	Study of C-C Chemokine Receptor 2 Alleles in Sarcoidosis, with Emphasis on Family-based Analysis 2005 ·American Journal of Respiratory and Critical Care Medicine ·Ruta Valentonyte,Jochen Hampe,Peter J.P. Croucher,Joachim Müller‐Quernheim,E. Schwinger,Stefan Schreiber,Manfred Schürmann	37
6	The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel diseasebreakdown → 2002 ·Gastroenterology ·Andrew Cuthbert,Sheila Fisher,Muddassar M. Mirza,Kathy King,Jochen Hampe,Peter J.P. Croucher,Silvia Mascheretti,Jeremy Sanderson,Alastair Forbes,John Mansfield,Stefan Schreiber,Cathryn M. Lewis,Christopher G. Mathew	523
7	Genomic structure, chromosome mapping and expression analysis of the human AVIL gene, and its exclusion as a candidate for locus for inflammatory bowel disease at 12q13–14 (IBD2) 2002 ·Gene ·Zeynep Tümer,Peter J.P. Croucher,Lars Riff Jensen,Jochen Hampe,Claus Hansen,Vera M. Kalscheuer,Hans Hilger Ropers,Niels Tommerup,Stefan Schreiber	15
8	Evidence for a NOD2 -independent susceptibility locus for inflammatory bowel disease on chromosome 16p 2001 ·Proceedings of the National Academy of Sciences ·Jochen Hampe,H Frenzel,Muddassar M. Mirza,Peter J.P. Croucher,Andrew Cuthbert,Silvia Mascheretti,Klaus Huse,Matthias Platzer,Stephen Bridger,Birgit Meyer,Peter Nürnberg,Pieter Stokkers,Michael Krawczak,Christopher G. Mathew,(unknown),Stefan Schreiber	82
9	Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populationsbreakdown → 2001 ·The Lancet ·Jochen Hampe,Andrew Cuthbert,Peter J.P. Croucher,Muddassar M. Mirza,Silvia Mascheretti,Sheila Fisher,H Frenzel,Kathy King,(unknown),(unknown),Stephen Bridger,Sander van Deventer,Alastair Forbes,Susanna Nikolaus,John Edward Lennard-Jones,Ulrich R. Foelsch,Michael Krawczak,Cathryn M. Lewis,Stefan Schreiber,Christopher G. Mathew	837

About Peter J.P. Croucher

Peter J.P. Croucher is a scholar working on Hematology, Cancer Research and Immunology and Allergy, having authored 9 papers that have together received 1.5k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (4 papers), Inflammatory Bowel Disease (4 papers) and Cancer Genomics and Diagnostics (3 papers). The work is most often cited by research in Genetics (1.0k citations), Immunology (648 citations) and Epidemiology (565 citations). Peter J.P. Croucher has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Stefan Schreiber, Jochen Hampe, Andrew Cuthbert, Christopher G. Mathew, Silvia Mascheretti, Muddassar M. Mirza, Kathy King, Alastair Forbes, Sheila Fisher and Cathryn M. Lewis. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Lancet and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact